These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 30367290)

  • 1. Fate of the Fc fusion protein aflibercept in retinal endothelial cells: competition of recycling and degradation.
    Deissler HL; Lang GK; Lang GE
    Graefes Arch Clin Exp Ophthalmol; 2019 Jan; 257(1):83-94. PubMed ID: 30367290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neonatal Fc receptor FcRn is involved in intracellular transport of the Fc fusion protein aflibercept and its transition through retinal endothelial cells.
    Deissler HL; Lang GK; Lang GE
    Exp Eye Res; 2017 Jan; 154():39-46. PubMed ID: 27836572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transport and fate of aflibercept in VEGF-A
    Deissler HL; Sommer K; Lang GK; Lang GE
    Exp Eye Res; 2020 Sep; 198():108156. PubMed ID: 32712182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Internalization of bevacizumab by retinal endothelial cells and its intracellular fate: Evidence for an involvement of the neonatal Fc receptor.
    Deissler HL; Lang GK; Lang GE
    Exp Eye Res; 2016 Feb; 143():49-59. PubMed ID: 26481553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Capacity of aflibercept to counteract VEGF-stimulated abnormal behavior of retinal microvascular endothelial cells.
    Deissler HL; Lang GK; Lang GE
    Exp Eye Res; 2014 May; 122():20-31. PubMed ID: 24631334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of Fc-receptors in the uptake and transport of therapeutic antibodies in the retinal pigment epithelium.
    Dithmer M; Hattermann K; Pomarius P; Aboul Naga SH; Meyer T; Mentlein R; Roider J; Klettner A
    Exp Eye Res; 2016 Apr; 145():187-205. PubMed ID: 26773870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. VEGF but not PlGF disturbs the barrier of retinal endothelial cells.
    Deissler HL; Deissler H; Lang GK; Lang GE
    Exp Eye Res; 2013 Oct; 115():162-71. PubMed ID: 23891860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. From sorting endosomes to exocytosis: association of Rab4 and Rab11 GTPases with the Fc receptor, FcRn, during recycling.
    Ward ES; Martinez C; Vaccaro C; Zhou J; Tang Q; Ober RJ
    Mol Biol Cell; 2005 Apr; 16(4):2028-38. PubMed ID: 15689494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Basic in vitro studies on VEGF inhibition with aflibercept: similarities and differences to other VEGF-binding therapeutic proteins].
    Lang GE; Lang GK; Deissler HL
    Klin Monbl Augenheilkd; 2015 Mar; 232(3):295-302. PubMed ID: 25393440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Direct demonstration of a neonatal Fc receptor (FcRn)-driven endosomal sorting pathway for cellular recycling of albumin.
    Schmidt EGW; Hvam ML; Antunes F; Cameron J; Viuff D; Andersen B; Kristensen NN; Howard KA
    J Biol Chem; 2017 Aug; 292(32):13312-13322. PubMed ID: 28637874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histological and Immunohistochemical Retinal Changes Following the Intravitreal Injection of Aflibercept, Bevacizumab and Ranibizumab in Newborn Rabbits.
    Cam D; Berk AT; Micili SC; Kume T; Ergur BU; Yilmaz O
    Curr Eye Res; 2017 Feb; 42(2):315-322. PubMed ID: 27314606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Half-life-extended recombinant coagulation factor IX-albumin fusion protein is recycled via the FcRn-mediated pathway.
    Chia J; Louber J; Glauser I; Taylor S; Bass GT; Dower SK; Gleeson PA; Verhagen AM
    J Biol Chem; 2018 Apr; 293(17):6363-6373. PubMed ID: 29523681
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Different effects of intravitreally injected ranibizumab and aflibercept on retinal and choroidal tissues of monkey eyes.
    Julien S; Biesemeier A; Taubitz T; Schraermeyer U
    Br J Ophthalmol; 2014 Jun; 98(6):813-25. PubMed ID: 24457369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aflibercept exhibits VEGF binding stoichiometry distinct from bevacizumab and does not support formation of immune-like complexes.
    MacDonald DA; Martin J; Muthusamy KK; Luo JK; Pyles E; Rafique A; Huang T; Potocky T; Liu Y; Cao J; Bono F; Delesque N; Savi P; Francis J; Amirkhosravi A; Meyer T; Romano C; Glinka M; Yancopoulos GD; Stahl N; Wiegand SJ; Papadopoulos N
    Angiogenesis; 2016 Jul; 19(3):389-406. PubMed ID: 27234973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differences in Uptake and Intracellular Fate between Bevacizumab and Aflibercept after Repetitive Long-Term Treatment in the Retinal Pigment Epithelium.
    Borchers L; Roider J; Klettner A
    Ophthalmic Res; 2021; 64(3):369-388. PubMed ID: 33011724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Localization of the human neonatal Fc receptor (FcRn) in human nasal epithelium.
    Heidl S; Ellinger I; Niederberger V; Waltl EE; Fuchs R
    Protoplasma; 2016 Nov; 253(6):1557-1564. PubMed ID: 26634928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Visualizing the site and dynamics of IgG salvage by the MHC class I-related receptor, FcRn.
    Ober RJ; Martinez C; Vaccaro C; Zhou J; Ward ES
    J Immunol; 2004 Feb; 172(4):2021-9. PubMed ID: 14764666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aflibercept Traps Galectin-1, an Angiogenic Factor Associated with Diabetic Retinopathy.
    Kanda A; Noda K; Saito W; Ishida S
    Sci Rep; 2015 Dec; 5():17946. PubMed ID: 26648523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of binding characteristics and in vitro activities of three inhibitors of vascular endothelial growth factor A.
    Yang J; Wang X; Fuh G; Yu L; Wakshull E; Khosraviani M; Day ES; Demeule B; Liu J; Shire SJ; Ferrara N; Yadav S
    Mol Pharm; 2014 Oct; 11(10):3421-30. PubMed ID: 25162961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Change in Diabetic Retinopathy Through 2 Years: Secondary Analysis of a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and Ranibizumab.
    Bressler SB; Liu D; Glassman AR; Blodi BA; Castellarin AA; Jampol LM; Kaufman PL; Melia M; Singh H; Wells JA;
    JAMA Ophthalmol; 2017 Jun; 135(6):558-568. PubMed ID: 28448655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.